Skip to content

High content imaging


Phenotypic changes in cell models can provide valuable insights about the efficacy, safety and mechanism of action of therapeutic candidates. High content imaging (HCI) applies automated microscopy, fluorescent imaging and multiparameter algorithms to visualize phenotypic changes. At Ncardia, we have the expertise to combine iPSC-derived healthy and diseased models with consistent HCI assays to help you make critical decisions faster and with higher confidence.

Assay
Benefits
  • 3D phenotypic characterization
  • Assessment of multiple targets simultaneously
  • Visualize complex cellular and sub-cellular structures
contact

Do you want to explore how this assay can help you progress your drug discovery programs? Contact an expert.

Applications

HCI based on iPSC-derived models enables the study of drug-induced morphological and spatial changes in the cells. It can be used as a primary screening for hit and lead identification or to visualize changes in more complex cellular systems during lead optimization. Our scientists optimize the assays and process the data to deliver relevant information on cell viability, proliferation, morphology or biomarker expression, among others.

Cardiac Neuron

High-throughput screening of anti-hypertrophy drugs based on NT-proBNP biomarker detection with high content imaging

To identify new treatments for cardiac hypertrophy, our scientists generated an iPSC-derived model of hypertrophic cardiomyopathy and used HCI for hit validation with 341 compounds. The intracellular expression of NT-proBNP biomarker was used as readout to determine the efficacy of the anti-hypertrophic hit compounds.

Representative confocal images of control and endothelin-1 treated human iPSC-derived cardiomyocytes stained for BNP hypertrophy biomarker (green) and DAPI (blue - nuclei).

Evaluation of lysosomal dysfunction in a human iPSC-derived model of Alzheimer’s disease with high content imaging.

Lysosomal dysfunction is a hallmark for neurodegeneration. Using HCI, we can detect lysotracker marker to localized lysosomes and determine the capacity of new therapeutic candidates to rescue lysosomal dysfunction.

Graph showing quantification of Lysotracker cell average intensity (RFU) in control and AD iPSC-derived model
Resources
Related assays
Questions about our assays?

Our work centers on a simple yet powerful premise: 
When we combine deep iPSC knowledge, broad assay capabilities and a demonstrated ability to integrate the biology of human diseases into preclinical research, we can help drug developers make critical decisions earlier and with more confidence.